Literature DB >> 35119558

Treatment strategy with multidrug therapy and tonsillectomy pulse therapy for childhood-onset severe IgA nephropathy.

Yukihiko Kawasaki1.   

Abstract

BACKGROUND: IgA nephropathy is a typical chronic glomerulonephritis that tends to occur in childhood.
METHOD: We reviewed the report on pathogenesis, treatment strategy with multidrug therapy and tonsillectomy pulse therapy for childhood-onset severe IgA nephropathy to clarify the pathophysiology and treatment of IgA nephropathy in childhood.
RESULTS: In recent years, it has been found that the pathogenesis at onset is associated with aberrant glycosylation at the IgA1 hinge. Given this genetic background, the aberrantly glycosylated IgA1immune complex produced by antigen-stimulated T cells and B cells is deposited in the glomeruli. Inflammation is induced via activation of the complement, macrophages and mesangial cells, and glomerular damage progresses thereafter. Treatment is selected according to the severity of IgA nephropathy. In order to prevent the development of renal damage, it is important to control the associated immune responses. For severe IgA nephropathy, in particular, multidrug therapy with prednisolone, immunosuppressants, and angiotensin enzyme synthesis inhibitors and tonsillectomy methylprednisolone pulse therapy are now performed- and, as a result, the number of renal deaths has decreased and the long-term prognosis has improved.
CONCLUSION: The prognosis of IgA nephropathy is improving. In the future, it will be important to develop a treatment method that takes into consideration the fact that children are in their growth and development stage and, therefore, seeks to minimizes side effects.
© 2022. Japanese Society of Nephrology.

Entities:  

Keywords:  IgA nephropathy; Multi-drugs combination therapy; Pathogenesis; Tonsillectomy; Treatment strategy

Mesh:

Substances:

Year:  2022        PMID: 35119558     DOI: 10.1007/s10157-022-02187-z

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  67 in total

1.  Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy.

Authors:  O Hotta; M Miyazaki; T Furuta; S Tomioka; S Chiba; I Horigome; K Abe; Y Taguma
Journal:  Am J Kidney Dis       Date:  2001-10       Impact factor: 8.860

Review 2.  IgA nephropathy.

Authors:  Robert J Wyatt; Bruce A Julian
Journal:  N Engl J Med       Date:  2013-06-20       Impact factor: 91.245

3.  A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group.

Authors:  N Yoshikawa; H Ito; T Sakai; Y Takekoshi; M Honda; M Awazu; K Ito; K Iitaka; Y Koitabashi; K Yamaoka; K Nakagawa; H Nakamura; S Matsuyama; Y Seino; N Takeda; S Hattori; M Ninomiya
Journal:  J Am Soc Nephrol       Date:  1999-01       Impact factor: 10.121

4.  Clinicopathological features and the prognosis of IgA nephropathy in Japanese children on long-term observation.

Authors:  R Nozawa; J Suzuki; A Takahashi; M Isome; Y Kawasaki; S Suzuki; H Suzuki
Journal:  Clin Nephrol       Date:  2005-09       Impact factor: 0.975

5.  Efficacy of multidrug therapy combined with mizoribine in children with diffuse IgA nephropathy in comparison with multidrug therapy without mizoribine and with methylprednisolone pulse therapy.

Authors:  Yukihiko Kawasaki; Mitsuaki Hosoya; Junzo Suzuki; Noriko Onishi; Ai Takahashi; Masato Isome; Ruriko Nozawa; Hitoshi Suzuki
Journal:  Am J Nephrol       Date:  2004-11-17       Impact factor: 3.754

6.  Treatment of severe IgA nephropathy in children.

Authors:  S P Andreoli; J M Bergstein
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

7.  Long-term prognosis and prognostic indices of IgA nephropathy in juvenile and in adult Japanese.

Authors:  Y Kusumoto; S Takebayashi; T Taguchi; T Harada; S Naito
Journal:  Clin Nephrol       Date:  1987-09       Impact factor: 0.975

8.  Combination therapy with mizoribine for severe childhood IgA nephropathy: a pilot study.

Authors:  Norishige Yoshikawa; Koichi Nakanishi; Kenji Ishikura; Hiroshi Hataya; Kazumoto Iijima; Masataka Honda
Journal:  Pediatr Nephrol       Date:  2008-01-26       Impact factor: 3.714

9.  Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial.

Authors:  Norishige Yoshikawa; Masataka Honda; Kazumoto Iijima; Midori Awazu; Shinzaburou Hattori; Koichi Nakanishi; Hiroshi Ito
Journal:  Clin J Am Soc Nephrol       Date:  2006-04-05       Impact factor: 8.237

10.  A digest from evidence-based clinical practice guideline for IgA nephropathy 2020.

Authors:  Hitoshi Suzuki; Masao Kikuchi; Kentaro Koike; Hiroyuki Komatsu; Keiichi Matsuzaki; Kazuo Takahashi; Daisuke Ichikawa; Masahiro Okabe; Yoko Obata; Ritsuko Katafuchi; Masao Kihara; Kaori Kohatsu; Takaya Sasaki; Akihiro Shimizu; Koichi Nakanishi; Akihiro Fukuda; Yoichi Miyazaki; Masahiro Muto; Hiroyuki Yanagawa; Yusuke Suzuki; Shoichi Fujimoto; Kengo Furuichi; Hirokazu Okada; Ichiei Narita
Journal:  Clin Exp Nephrol       Date:  2021-09-26       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.